About
Basic Data Updated:
1 month agoThe Corporate was formerly known as Biocon Biologics India Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3,507.50 cr and a paid-up capital of Rs 1,321.70 cr.
The Corporate currently has active open charges totaling ₹20,781.03 cr. It has already closed loans amounting to ₹100.00 cr, as per the Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Biocon Biologics Limited India are Deepika Srivastava as Company Secretary, Shreehas Tambe as Ceo, and Mr Upadhye as Cfo. Bobby Parikh, Kiran Shaw, Nivruti Rai, and Seven other members serve as directors at the Company.
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Website12224421
- Telephone12224421
- Email Address12224421
- Social Media12224421
| CIN/LLPIN/FCRN | U24119KA2016PLC093936 |
| Company No. | 093936 |
| Company Classification | Public Limited Indian Non-Government Company |
| Incorporation Date | 08 Jun 2016 |
| Date of AGM | 28 Jul 2023 |
| Date of Balance Sheet | 31 Mar 2023 |
| Listing Status | Unlisted |
| ROC Code | Roc Bangalore |
Financials of Biocon Biologics Limited
Corporate Structure
Unlock access to Biocon Biologics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
People in Biocon Biologics Limited
Unlock and access historical data on people associated with Biocon Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Executive Team (3)
DS
Deepika Srivastava
Company SecretaryAppointment Date: 14-Feb-2023
Status: Current
ST
Shreehas Tambe CEOAppointment Date: 05-Dec-2022
Status: Current
MU
Mr Upadhye CFOStatus: Current
Board Members(9)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 06 Mar 2023 | ₹9,841.76 Cr | Open |
Others Creation Date: 03 Mar 2023 | ₹9,841.76 Cr | Open |
Others Creation Date: 13 Sep 2021 | ₹200.00 Cr | Open |
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biocon Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biocon Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alert
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Related Corporates (Common Directorship)
39 years 6 months 
Recent activity within the organization
Annual General Meeting
Biocon Biologics Limited last Annual general meeting of members was held on 28 Jul 2023 as per latest MCA records.
28 Jul 2023Balance Sheet
Biocon Biologics Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Bangalore.
31 Mar 2023Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 9,841.76 cr with Charge ID 100701655 was registered on 06 Mar 2023.
06 Mar 2023Charges
A charge with Others amounted to Rs. 9,841.76 cr with Charge ID 100692461 was registered on 03 Mar 2023.
03 Mar 2023Director Appointment
Rajiv Malik was appointed as a Nominee Director was appointed as a Nominee Director on 29 Nov 2022 & has been associated with this company since 1 year 6 months .
29 Nov 2022
Recent News, Updates & Announcement
- European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocons Proposed Biosimilars Trastuzumab and Pegfilgrastim.
PRNewswire Mylan NV NASDAQ TASE MYL and Biocon Ltd BSE code 532523 NSE BIOCON today announced that the European Medicines Agency EMA has.
PR Newswire 30 Nov 2017
- Biocon Introduces Oncologic Biosimilar KRABEVA In India.
Medicalbuyer 27 Nov 2017
- Biocon launches biosimilar bevacizumab for cancer treatment in India Mint.
Biocons biosimilar bevacizumab is indicated as a firstline treatment of patients with metastatic colorectal cancer and also used to treat lung kidney cervical ovarian and brain cancers.
mint 24 Nov 2017
Frequently asked questions
What is the Incorporation or founding date of Biocon Biologics Limited?
